Kissei Pharmaceutical Co., Ltd. 4547
TSE · Japan · Gesundheitstechnologie
¥3.720,00-110,00 (-2,87 %)
Markt geöffnet· · JPY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geöffnet· · JPY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
The latest analyst update on Rigel Pharmaceuticals centers on a higher assessed fair value, which has moved from US$51.6 to US$61.2 per share in the current model. Analysts link this shift to how they view Veppanu in the U.S. and the ex U.S. potential of Rezlidhia under the Kissei partnership, with both products seen as key to supporting or challenging the new valuation. As you read on, you will see how to track this evolving narrative and what it could mean for your own view of Rigel...
Kissei Pharmaceutical (TSE:4547) cut its earnings guidance for the six months to September 2026 and the full year to March 2027 after TAVNEOS sales lagged expectations, affecting revenue forecasts and projected profitability. See our latest analysis for Kissei Pharmaceutical. The earnings guidance cut has come as Kissei Pharmaceutical’s share price sits at ¥4,160, with a 1-day share price return of 3.74% and a year-to-date share price return that is down 9.86%. The 5-year total shareholder...
Amgen Inc.’s (NASDAQ:AMGN) Japanese partner Kissei Pharmaceutical Co., Ltd. said it has started information-sharing activities in Japan, urging healthcare professionals to carefully evaluate the use of Tavneos (avacopan) following safety and regulatory concerns raised in the U.S. and Europe. Kissei Advises Doctors To Exercise Caution On Tavneos The company said physicians should avoid prescribing the drug to new patients and reassess continued treatment for current users while considering risks
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.